低剂量与标准剂量艾多沙班对老年非瓣膜性房颤患者抗凝治疗的效果研究

Study on the Effect of Low-dose and Standard-dose Idoxaban on Anticoagulant Therapy in Elderly Patients with Nonvalvular Atrial Fibrillation

目的:比较低剂量与标准剂量艾多沙班对非瓣膜性老年房颤(non valvular artial fi brillation,NVAF)患者抗凝治疗的效果。方法:抽选2020年5月—2020年11月在本院接受治疗的75例NVAF患者,根据艾多沙班用药剂量不同将其分为A组(n=25)、B组(n=26)、C组(n=24)。A组、B组、C组分别接受剂量为60 mg/d、30 mg/d、15 mg/d的艾多沙班进行抗凝治疗,且均连续服药6个月,比较3组栓塞事件、出血事件发生率、凝血功能[凝血酶时间(TT)]、肝肾功能[肌酐(Scr)、血尿素氮(BUN)、谷丙转氨酶(ALT)水平]。结果:治疗后,3组栓塞事件和出血事件发生率比较,差异无统计学意义(P>0.05)。3组TT、ALT比较,差异无统计学意义(P>0.05);B、C组BUN、Scr低于A组,差异有统计学意义(P<0.05)。结论:相较于60 mg/d标准剂量,低剂量艾多沙班在老年NVAF患者抗凝治疗中同样可取得理想的抗凝效果,且对肾功能影响更小。

Objective: To compare the effects of low-dose and standard-dose idoxaban on anticoagulant therapy in patients with non-valvular artial fibrillation(NVAF). Methods: A selection of 75 patients with NVAF who were treated in our hospital from May 2020 to November 2020, and divided them into group A(n = 25) and group B(n = 26) according to the dose of idoxaban.), Group C(n= 24). Group A, Group B, and Group C received anticoagulant therapy with idoxaban at doses of 60 mg/d, 30 mg/d, and 15 mg/d, and they all took the drug for 6 consecutive months. The embolic events, The incidence of bleeding events, blood coagulation function [thrombin time(TT)], liver and kidney function [creatinine(Scr), blood urea nitrogen(BUN), alanine aminotransferase(ALT) level] were compared among the three groups. Results: After treatment, there were no significant difference in the incidence of embolic events and bleeding events in the three groups(P>0.05). There were no significant difference in TT and ALT among the three groups(P>0.05). The level of BUN and Scr in groups B and C were lower than those in group A, and the difference was statistically significant(P<0.05). Conclusion: Compared with the standard dose of 60 mg/d, low-dose idoxaban can also achieve the ideal anticoagulant effect in the anticoagulant treatment of elderly NVAF patients, and has a smaller effect on renal function.